These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22046562)

  • 1. One-Year Safety Analysis of the COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133 Bone Marrow Stem Cells to Placebo in Patients after Acute Myocardial Infarction and Left Ventricular Dysfunction.
    Mansour S; Roy DC; Bouchard V; Stevens LM; Gobeil F; Rivard A; Leclerc G; Reeves F; Noiseux N
    Bone Marrow Res; 2011; 2011():385124. PubMed ID: 22046562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COMPARE-AMI trial: comparison of intracoronary injection of CD133+ bone marrow stem cells to placebo in patients after acute myocardial infarction and left ventricular dysfunction: study rationale and design.
    Mansour S; Roy DC; Bouchard V; Nguyen BK; Stevens LM; Gobeil F; Rivard A; Leclerc G; Reeves F; Noiseux N
    J Cardiovasc Transl Res; 2010 Apr; 3(2):153-9. PubMed ID: 20560029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the COMPARE-AMI trial: First report of long-term safety of CD133+ cells.
    Haddad K; Potter BJ; Matteau A; Reeves F; Leclerc G; Rivard A; Gobeil F; Roy DC; Noiseux N; Mansour S
    Int J Cardiol; 2020 Nov; 319():32-35. PubMed ID: 32553596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and rationale for the Myocardial Stem Cell Administration After Acute Myocardial Infarction (MYSTAR) Study: a multicenter, prospective, randomized, single-blind trial comparing early and late intracoronary or combined (percutaneous intramyocardial and intracoronary) administration of nonselected autologous bone marrow cells to patients after acute myocardial infarction.
    Nyolczas N; Gyöngyösi M; Beran G; Dettke M; Graf S; Sochor H; Christ G; Edes I; Balogh L; Krause KT; Jaquet K; Kuck KH; Benedek I; Hintea T; Kiss R; Préda I; Kotevski V; Pejkov H; Dudek D; Heba G; Sylven C; Charwat S; Jacob R; Maurer G; Lang I; Glogar D
    Am Heart J; 2007 Feb; 153(2):212.e1-7. PubMed ID: 17239678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stem cell therapy for the broken heart: mini-organ transplantation.
    Mansour S; Roy DC; Lemieux B; Ouellet C; Stevens LM; Noiseux N
    Transplant Proc; 2009 Oct; 41(8):3353-7. PubMed ID: 19857748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study to evaluate the safety and feasibility of intracoronary CD133(+) and CD133(-) CD34(+) cell therapy in patients with nonviable anterior myocardial infarction.
    Manginas A; Goussetis E; Koutelou M; Karatasakis G; Peristeri I; Theodorakos A; Leontiadis E; Plessas N; Theodosaki M; Graphakos S; Cokkinos DV
    Catheter Cardiovasc Interv; 2007 May; 69(6):773-81. PubMed ID: 17394248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With ST-Segment Elevation Myocardial Infarction and Left Ventricular Dysfunction.
    Fernández-Avilés F; Sanz-Ruiz R; Bogaert J; Casado Plasencia A; Gilaberte I; Belmans A; Fernández-Santos ME; Charron D; Mulet M; Yotti R; Palacios I; Luque M; Sádaba R; San Román JA; Larman M; Sánchez PL; Sanchís J; Jiménez MF; Claus P; Al-Daccak R; Lombardo E; Abad JL; DelaRosa O; Corcóstegui L; Bermejo J; Janssens S
    Circ Res; 2018 Aug; 123(5):579-589. PubMed ID: 29921651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety.
    Bartunek J; Vanderheyden M; Vandekerckhove B; Mansour S; De Bruyne B; De Bondt P; Van Haute I; Lootens N; Heyndrickx G; Wijns W
    Circulation; 2005 Aug; 112(9 Suppl):I178-83. PubMed ID: 16159812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (REPAIR-AMI) cardiac magnetic resonance imaging substudy.
    Dill T; Schächinger V; Rolf A; Möllmann S; Thiele H; Tillmanns H; Assmus B; Dimmeler S; Zeiher AM; Hamm C
    Am Heart J; 2009 Mar; 157(3):541-7. PubMed ID: 19249426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial.
    Tendera M; Wojakowski W; Ruzyłło W; Chojnowska L; Kepka C; Tracz W; Musiałek P; Piwowarska W; Nessler J; Buszman P; Grajek S; Breborowicz P; Majka M; Ratajczak MZ;
    Eur Heart J; 2009 Jun; 30(11):1313-21. PubMed ID: 19208649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COMPARE CPM-RMI Trial: Intramyocardial Transplantation of Autologous Bone Marrow-Derived CD133+ Cells and MNCs during CABG in Patients with Recent MI: A Phase II/III, Multicenter, Placebo-Controlled, Randomized, Double-Blind Clinical Trial.
    Naseri MH; Madani H; Ahmadi Tafti SH; Moshkani Farahani M; Kazemi Saleh D; Hosseinnejad H; Hosseini S; Hekmat S; Hossein Ahmadi Z; Dehghani M; Saadat A; Mardpour S; Hosseini SE; Esmaeilzadeh M; Sadeghian H; Bahoush G; Bassi A; Amin A; Fazeli R; Sharafi Y; Arab L; Movahhed M; Davaran S; Ramezanzadeh N; Kouhkan A; Hezavehei A; Namiri M; Kashfi F; Akhlaghi A; Sotoodehnejadnematalahi F; Vosough Dizaji A; Gourabi H; Syedi N; Shahverdi AH; Baharvand H; Aghdami N
    Cell J; 2018 Jul; 20(2):267-277. PubMed ID: 29633605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized double-blind control study of early intra-coronary autologous bone marrow cell infusion in acute myocardial infarction: the REGENERATE-AMI clinical trial†.
    Choudry F; Hamshere S; Saunders N; Veerapen J; Bavnbek K; Knight C; Pellerin D; Locca D; Westwood M; Rakhit R; Crake T; Kastrup J; Parmar M; Agrawal S; Jones D; Martin J; Mathur A
    Eur Heart J; 2016 Jan; 37(3):256-63. PubMed ID: 26405233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial.
    Schächinger V; Assmus B; Britten MB; Honold J; Lehmann R; Teupe C; Abolmaali ND; Vogl TJ; Hofmann WK; Martin H; Dimmeler S; Zeiher AM
    J Am Coll Cardiol; 2004 Oct; 44(8):1690-9. PubMed ID: 15489105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial.
    Hirsch A; Nijveldt R; van der Vleuten PA; Tijssen JG; van der Giessen WJ; Tio RA; Waltenberger J; ten Berg JM; Doevendans PA; Aengevaeren WR; Zwaginga JJ; Biemond BJ; van Rossum AC; Piek JJ; Zijlstra F;
    Eur Heart J; 2011 Jul; 32(14):1736-47. PubMed ID: 21148540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effect of intracoronary infusion of mobilized peripheral blood stem cells by granulocyte colony-stimulating factor on left ventricular function and remodeling in patients with acute myocardial infarction versus old myocardial infarction: the MAGIC Cell-3-DES randomized, controlled trial.
    Kang HJ; Lee HY; Na SH; Chang SA; Park KW; Kim HK; Kim SY; Chang HJ; Lee W; Kang WJ; Koo BK; Kim YJ; Lee DS; Sohn DW; Han KS; Oh BH; Park YB; Kim HS
    Circulation; 2006 Jul; 114(1 Suppl):I145-51. PubMed ID: 16820564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and Design of a Clinical Trial to Evaluate the Safety and Efficacy of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction: The Randomized Multicenter Double-Blind Controlled CAREMI Trial (Cardiac Stem Cells in Patients With Acute Myocardial Infarction).
    Sanz-Ruiz R; Casado Plasencia A; Borlado LR; Fernández-Santos ME; Al-Daccak R; Claus P; Palacios I; Sádaba R; Charron D; Bogaert J; Mulet M; Yotti R; Gilaberte I; Bernad A; Bermejo J; Janssens S; Fernández-Avilés F
    Circ Res; 2017 Jun; 121(1):71-80. PubMed ID: 28533209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of intracoronary autologous bone marrow cells on left ventricular function in acute myocardial infarction: a systematic review and meta-analysis for randomized controlled trials.
    Kang S; Yang YJ; Li CJ; Gao RL
    Coron Artery Dis; 2008 Aug; 19(5):327-35. PubMed ID: 18607170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.
    Traverse JH; Henry TD; Vaughan DE; Ellis SG; Pepine CJ; Willerson JT; Zhao DX; Simpson LM; Penn MS; Byrne BJ; Perin EC; Gee AP; Hatzopoulos AK; McKenna DH; Forder JR; Taylor DA; Cogle CR; Baraniuk S; Olson RE; Jorgenson BC; Sayre SL; Vojvodic RW; Gordon DJ; Skarlatos SI; Moyè LA; Simari RD;
    Tex Heart Inst J; 2010; 37(4):412-20. PubMed ID: 20844613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combined effect of subcutaneous granulocyte- colony stimulating factor and myocardial contrast echocardiography with intravenous infusion of sulfur hexafluoride on post-infarction left ventricular function, the RIGENERA 2.0 trial: study protocol for a randomized controlled trial.
    Leone AM; D'Amario D; Teofili L; Basile E; Cannata F; Graziani F; Marzilli M; Russo AM; Tarantini G; Ceconi C; Leone G; Trani C; Rebuzzi AG; Crea F
    Trials; 2016 Feb; 17():97. PubMed ID: 26891753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous CD133+ bone marrow cells and bypass grafting for regeneration of ischaemic myocardium: the Cardio133 trial.
    Nasseri BA; Ebell W; Dandel M; Kukucka M; Gebker R; Doltra A; Knosalla C; Choi YH; Hetzer R; Stamm C
    Eur Heart J; 2014 May; 35(19):1263-74. PubMed ID: 24497345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.